ArticleClinical kidney journal2025
Impact of albuminuria screening in primary care on the detection and management of chronic kidney disease: findings from the ONDAAS study.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older: A Population-Based Cohort Study.Journal of clinical medicine · 2026Article
- Impact of office and home blood pressure control on cardiovascular events in relation to KDIGO risk categories: findings from the J-HOP study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Diagnostic accuracy of UACR in CKD screening among diabetics: A community study.Bioinformation · 2026Article
- From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 Diabetes Mellitus and CKD.Kidney international reports · 2026Review
- A Pilot Study of Opportunistic Chronic Kidney Disease Screening in Primary Care Using a Clinical Decision Support System.Diagnostics (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence and burden of chronic kidney disease (CKD) is increasing. Despite available early detection methods, many individuals with CKD remain undiagnosed. We evaluate the effectiveness of albuminuria screening for early detection and management of CKD in the primary care setting. Methods: We conducted a cross-sectional, multicenter epidemiological study in primary care centers in the province of Burgos, Spain, from February to May 2024. The urinary albumin:creatinine ratio (uACR) was assessed in 9890 adults attending primary care visits. The primary finding was the prevalence of CKD defined by KDIGO guidelines thresholds for albuminuria and estimated glomerular filtration rate (eGFR), stratified by age, gender and motive for consultation. Results: In total, 22.29% of participants met CKD criteria, with 14.04% showing uACR levels above 30 mg/g (albuminuria categories A2-A3) and 12.81% displaying reduced eGFR levels (categories G3-G5). Albuminuria screening identified CKD in 1338 (14.1%) participants, including 903 (10.88%) individuals with eGFR >60 mL/min/1.73 m² and 434 (35.57%) participants with CKD upgraded to higher risk due to albuminuria. Among individuals with CKD, 2123 (22.29%) participants were eligible for therapies to slow disease progression, per current KDIGO guidelines. Conclusion: The ONDAAS study reveals a high prevalence of CKD among individuals attending primary care facilities, emphasizing the importance of albuminuria screening for early detection and risk stratification of CKD. Our findings demonstrate how early screening can significantly shape therapeutic choices and ultimately enhance patient care outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.